Category: Uncategorized

Shop with AmazonSmile to Support the Carcinoid Cancer Foundation

Thanksgiving is only 2 days away and Black Friday is nearly here. Shopping for holiday gifts? Here’s a great way to support the Carcinoid Cancer Foundation while shopping at amazon.com.

When you do your holiday shopping at AmazonSmile, Amazon donates…

Josh Mailman’s Patient Perspective on Integrative Oncology

“A Patient’s Perspective on Integrative Oncology:  Getting Past the ‘War,’ Living with and Beyond Cancer” by Josh Mailman has been published in the November 2014 issue of the Journal of the National Cancer Institute Monographs focused on Integrative…

Happy New Year from the Carcinoid Cancer Foundation

As 2012 draws to a close, the Carcinoid Cancer Foundation would like to thank each of you for your support.  This year has been especially exciting because of our work on the Worldwide NET Cancer Awareness Day Alliance, with Grace Goldstein, CCF’s Chief…

National Carcinoid and NET Patient Conference: Have You Registered?

Have you registered for the national carcinoid and NET patient conference in New Orleans, September 20 – 22?  The hotel is over 90% booked and registration is nearing capacity!  This is a wonderful opportunity to learn more about carcinoid and …

Steve Jobs to Take New Medical Leave from Apple

Steve Jobs, CEO and co-founder of Apple and the most well-known member of the carcinoid and neuroendocrine tumor community, is taking a new medical leave of absence.  This announcement was reported today, January 17, 2011, by The New York Times, a year…

Governors of Arkansas and Michigan Support NET Cancer Awareness Day

Mike Beebe, Governor of Arkansas, and Jennifer M. Granholm, Governor of Michigan, are the 9th and 10th United States Governors to issue proclamations in support of the first Worldwide NET Cancer Awareness Day on November 10, 2010.

With less than 24 hours…

FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)

For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…

Happy 4th of July from The Carcinoid Cancer Foundation

Octreoscan Test for Carcinoid & NET Patients Currently on Hold in U.S. and Canada

Due to a voluntary recall by the drug company Covidien, the Octreoscan Kit using Indium In-111 pentetreotide is not available at the present time in the United States or Canada.  This means that carcinoid and neuroendocrine tumor patients cannot have…

BlogCatalog

The Carcinoid Cancer Foundation (CCF) is pleased to announce that the Foundation’s blog has been selected for inclusion in BlogCatalog, a premiere Internet directory of blogs on subjects ranging from health and medicine to technology to education …